You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Moderna(MRNA.US)一季度營收淨利潤雙雙大增2倍
格隆匯 05-04 20:18
格隆匯5月4日丨Moderna(MRNA.US)公佈2022年第一季度業績,營收60.66億美元,同比增長213%,超出市場預期;淨利潤為36.57億美元,同比增長200%;攤薄後每股收益為8.58美元,超出市場預期,上年同期為2.84美元。其中,新冠疫苗銷售額為59億美元,預期為50.5億美元,上年同期為17億美元。Moderna預計第二季度將有四個項目進入第三階段試驗,包括:針對Omicron等變體的二價新冠疫苗加強針、流感疫苗、呼吸道合胞病毒(RSV)疫苗、鉅細胞病毒(CMV)疫苗。公司還預計,受新冠疫情的影響,2022年下半年的銷售額略高於上半年。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account